Journal Watch · Autoimmunity Reviews · 2026

Kidney failure in patients with ANCA-associated vasculitis: A systematic review of outcomes.

However, the pooled estimates should be used with caution, given the high heterogeneity in patient characteristics across studies.

Kronbichler A, Ramirez de Arellano A, Cattin J, Hunt BAutoimmunity Reviews3 min readPharma relevance 75/100

DOI: 10.1016/j.autrev.2026.104125PMID: 42349595Study type: meta-analysis / systematic review

TL;DR

However, the pooled estimates should be used with caution, given the high heterogeneity in patient characteristics across studies.

Key findings

  • The meta-analysis found that ESKD incidence was 14.2% and 24.8% at 1 and 10 years of follow-up, respectively, and that 1 mL/min/1.73 m<sup>2</sup> higher eGFR at diagnosis and at 6 months after diagnosis were associated with 5-6% and 7-8% reductions in ESKD risk, respectively.<h4>Conclusions</h4>This review indicates that patients with AAV remain at high risk of ESKD, with lower eGFR at diagnosis and at 6 months after diagnosis associated with poorer kidney outcomes.
  • However, the pooled estimates should be used with caution, given the high heterogeneity in patient characteristics across studies.

Numbers at a glance (from the abstract)

59.6%51.4%14.2%24.8%6%8%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Combined estimates of the cumulative incidence of ESKD and hazard ratios (HRs) quantifying the relationship between eGFR and ESKD risk were calculated.<h4>Results</h4>A total of 49 studies (19,301 patients) reported the incidence of ESKD, while 19 studies (4513 patients) reported the relationship between eGFR and ESKD risk. ESKD incidence ranged from 2.9 to 59.6% at 1 year of follow-up, and from 9.4 to 51.4% at 10 years.

Full abstract (original)

Background: <h4>Introduction</h4>Kidney involvement in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) significantly increases morbidity and risk of mortality, particularly with progression to end-stage kidney disease (ESKD). This review focused on the cumulative incidence of ESKD in patients with AAV and assessed how changes in estimated glomerular filtration rate (eGFR) impact the risk of developing ESKD.<h4>Methods</h4>Literature searches were performed in the PubMed, EMBASE and Cochrane Library databases, focusing on studies published in 2019-2024 with at least 100 participants and a minimum follow-up of 3 years.

What they did: Combined estimates of the cumulative incidence of ESKD and hazard ratios (HRs) quantifying the relationship between eGFR and ESKD risk were calculated.<h4>Results</h4>A total of 49 studies (19,301 patients) reported the incidence of ESKD, while 19 studies (4513 patients) reported the relationship between eGFR and ESKD risk. ESKD incidence ranged from 2.9 to 59.6% at 1 year of follow-up, and from 9.4 to 51.4% at 10 years.

Results & conclusions: The meta-analysis found that ESKD incidence was 14.2% and 24.8% at 1 and 10 years of follow-up, respectively, and that 1 mL/min/1.73 m<sup>2</sup> higher eGFR at diagnosis and at 6 months after diagnosis were associated with 5-6% and 7-8% reductions in ESKD risk, respectively.<h4>Conclusions</h4>This review indicates that patients with AAV remain at high risk of ESKD, with lower eGFR at diagnosis and at 6 months after diagnosis associated with poorer kidney outcomes. However, the pooled estimates should be used with caution, given the high heterogeneity in patient characteristics across studies.

Abstract © the authors / Autoimmunity Reviews (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.autrev.2026.104125 · PubMed 42349595.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, gene therapy — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · gene therapy

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.

Frequently asked questions

What did this Autoimmunity Reviews study find?

However, the pooled estimates should be used with caution, given the high heterogeneity in patient characteristics across studies.

What type of study is this?

It is a meta-analysis / systematic review, published in Autoimmunity Reviews in 2026. Combined estimates of the cumulative incidence of ESKD and hazard ratios (HRs) quantifying the relationship between eGFR and ESKD risk were calculated.<h4>Results</h4>A total of 49 studies (19,301 patients) reported the incidence of ESKD, while 19 studies (4513 patients) reported the relationship between eGFR and ESKD risk.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.autrev.2026.104125. PubMed ID: 42349595. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Kronbichler A, Ramirez de Arellano A, Cattin J, Hunt B. Kidney failure in patients with ANCA-associated vasculitis: A systematic review of outcomes.. Autoimmunity Reviews (2026). DOI: 10.1016/j.autrev.2026.104125.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/kidney-failure-in-patients-with-anca-associated-vasculitis-a-systematic-104125/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides